Lifang Lv
- Cancer Research top 10%
-
- Diabetes Treatment and Management 4
- Diabetes Management and Research 3
-
- Metabolism, Diabetes, and Cancer 3
-
- Cardiac Fibrosis and Remodeling 5
-
- Cardiovascular, Neuropeptides, and Oxidative Stress Research 2
-
- Apelin-related biomedical research 2
-
- Peptidase Inhibition and Analysis 2
-
- Nuclear Receptors and Signaling 2
- Journals
- Biochemical Pharmacology (1 paper)European Journal of Pharmacology (2 papers)Journal of Cellular Physiology (1 paper)
- Partner nations
- ChinaSwitzerlandKenya
In The Last Decade
Lifang Lv
19 papers receiving 558 citations
Peers
Comparison fields: 5 of 88
- Cancer Research 209
- Endocrinology, Diabetes and Metabolism 82
- Molecular Biology 328
- Cardiology and Cardiovascular Medicine 96
- Cell Biology 53
Countries citing papers authored by Lifang Lv
This map shows the geographic impact of Lifang Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifang Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifang Lv more than expected).
Fields of papers citing papers by Lifang Lv
This network shows the impact of papers produced by Lifang Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifang Lv. The network helps show where Lifang Lv may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lifang Lv, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 7 | |
| 3 | 2022 | 12 | |
| 4 | 2022 | 17 | |
| 5 | 2020 | 12 | |
| 6 | 2020 | 11 | |
| 7 | 2019 | 96 | |
| 8 | 2018 | 1 | |
| 9 | 2018 | 73 | |
| 10 | 2017 | 99 | |
| 11 | 2016 | 12 | |
| 12 | 2016 | 70 | |
| 13 | 2015 | 5 | |
| 14 | 2015 | 15 | |
| 15 | 2015 | 1 | |
| 16 | 2014 | 43 | |
| 17 | 2014 | 9 | |
| 18 | 2014 | 3 | |
| 19 | 2011 | 76 |
About Lifang Lv
Lifang Lv is a scholar working on Cancer Research, Endocrinology, Diabetes and Metabolism and Physiology, having authored 19 papers that have together received 564 indexed citations. Recurring topics across this work include Cardiac Fibrosis and Remodeling (5 papers), Diabetes Treatment and Management (4 papers), Diabetes Management and Research (3 papers), Metabolism, Diabetes, and Cancer (3 papers), Cardiovascular, Neuropeptides, and Oxidative Stress Research (2 papers), Apelin-related biomedical research (2 papers), Peptidase Inhibition and Analysis (2 papers) and Nuclear Receptors and Signaling (2 papers). The work is most often cited by research in Cancer Research (209 citations), Endocrinology, Diabetes and Metabolism (82 citations) and Molecular Biology (328 citations). Lifang Lv has collaborated with scholars based in China, Switzerland and Kenya. Frequent co-authors include Hongli Shan, Yuhong Zhou, Xuelian Li, Haihai Liang, Rui Yang, Xiaoguang Zhao, Lanlan Chen, Yingqi Liu, Yingnan Li and Chaoqian Xu. Their work appears in journals such as Biochemical Pharmacology, European Journal of Pharmacology and Journal of Cellular Physiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.